SCHEMBL3325014

SCHEMBL3325014

CC(C)[Si](C(C)C)(C(C)C)n1ccc2cc(C3CN(C(=O)OC(C)(C)C)C3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 7/20 0.40
▸ USP30 Q70CQ3 1/20 0.38
▸ RORC P51449 1/20 0.37
▸ SLC34A1 Q06495 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ PIK3CD O00329 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ EGFR P00533 2/20 0.36
▸ HCK P08631 2/20 0.36
▸ SRC P12931 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CB P42338 2/20 0.36
▸ MTOR P42345 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ EPHB4 P54760 2/20 0.36
▸ PRKDC P78527 2/20 0.36
▸ PI4KB Q9UBF8 2/20 0.36
▸ NAMPT P43490 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202837 0.79 MAPT (0.47) NAMPTGPR119
SCHEMBL442724 0.78 USP30 (0.42) USP30ABL1GPR119
SCHEMBL20694910 0.78 ADAMTS5 (0.43) GPR119
SCHEMBL19759000 0.78 ADAMTS5 (0.43) GPR119
SCHEMBL29849392 0.76 PDE1C (0.47) PDE4BUSP30SLC34A1GPR119
SCHEMBL21385205 0.76 PDE1C (0.47) PDE4BUSP30SLC34A1GPR119
SCHEMBL3326736 0.75 HTR6 (0.46) PDE4BGPR119
SCHEMBL29196983 0.75 PDE4B (0.44) PDE4BUSP30RORCSLC34A1KDM4E
SCHEMBL3327338 0.74 HTR6 (0.49) RORC
SCHEMBL28623603 0.73 HTR6 (0.44) PDE4BGPR119NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507469-B2 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor ABBOTT GMBH & CO. KG (DE) 2013-08-13 — — US disclosed
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2010-06-03 — — US disclosed
EP-2155724-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2010-02-24 — — EP disclosed
WO-2008116833-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2008-10-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137280-A1 AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR HTR6, HTR4, HTR3C PDE4B 3245/4885USP30 1782/4885RORC 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback